21
and there are no specific therapeutic modalities to forestall injury or promote repair once renal 22 injurious pathways become initiated.
23
Most cases of AKI are caused by ischemia, which may arise as a consequence of diverse 24 medical conditions, surgery, or iatrogenically. Ischemic AKI can be differentiated from purely 
28
and repair nevertheless continues to stymie specific and effective therapeutic approaches (3).
29
Macrophage migration inhibitory factor (MIF) is the first cytokine activity to be 30 described (1), and when cloned was soon found to be widely expressed in both immune and 
67
The main physiological function of SLPI is to buffer extracellular protease-mediated effects by 
